Partnership led by UK Medical Research Council to invest more than $368 million in medical technology
The UK’s Chancellor of the Exchequer, George Osborne, has announced that a partnership led by the Medical Research Council is to invest more than £230 million ($368 million) in technologies to identify causes of diseases such as cancer and dementia.
These will be used to establish differences in the cellular and molecular makeup of patients affect how they respond to diseases and treatment as part of the Clinical Research Infrastructure Initiative.
Funding will come from the UK government, devolved regional administrations, Arthritis Research UK, the British Heart Foundation, the Wellcome Trust and Cancer Research UK. It will take place in 23 key projects at centers across the country, including research teams at 15 universities, and many of these will involve partnering between academic researchers and pharma and biotech companies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze